12:00 AM
 | 
Mar 02, 2009
 |  BC Week In Review  |  Company News  |  Other News

La Jolla Pharmaceutical autoimmune, inflammation news

La Jolla will reduce headcount by an undisclosed number and evaluate strategic options, including a sale or wind down of the business after the company stopped the Phase III ASPEN trial of Riquent abetimus...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >